IRVINE, Calif., Oct. 29, 2021 /PRNewswire/ -- AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced the publication of the peer-reviewed manuscript, "Co-grafts of Human Stem Cell Derived Retina Organoids and Retinal Pigment Epithelium for Retinal Reconstruction in Immunodeficient Retinal Degenerate Royal College of Surgeons Rats," in the journal Frontiers in Neuroscience. The study, led by researchers at AIVITA Biomedical and the Stem Cell Research Center at the University of California, Irvine, used retina organoids and polarized retinal pigment epithelium sheets generated from human stem cells developed by AIVITA to test their viability as a "total retina patch" for vision loss.
In this study, in vivo transplantation experiments were conducted in immunodeficient Royal College of Surgeons rats at advanced stages of retinal degeneration. Structural reconstruction of the severely damaged retina was observed in transplanted animals based on histological assessments and optical coherence tomography imaging. Visual function assessments were conducted by optokinetic behavioral testing and superior collicus electrophysiology. Long-term survival of the co-graft in the rat subretinal space and improvement in visual function were observed. Immunohistochemistry showed that the co-grafts grew, generated new photoreceptors and developed neuronal processes that were integrated into the host retinal.
"These findings demonstrate the potential of this approach in treating common retinal degenerative conditions such as end-stage age-related macular degeneration, retinitis pigmentosa, and retinal damage due to injury," said Dr. Hans S. Keirstead, AIVITA Biomedical's chairman and CEO.
About AIVITA Biomedical
Founded in 2016 by pioneers in the cell therapy industry, AIVITA Biomedical, Inc. utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its therapeutic pipeline. Our cancer immunotherapy targets the seed of all cancers, tumor-initiating stem cells, with a unique pan-antigenic approach that targets all neoantigens specific to the patient's cancer. Our patient-specific cancer treatments have shown tremendous promise in eradicating tumors, without harmful side effects, in melanoma and glioblastoma clinical studies.
Cautionary Note Regarding Forward-Looking Statements
This communication contains statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on a number of assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.
SOURCE AIVITA Biomedical, Inc.